scorecardresearch
Add as a preferred source on Google
Wednesday, April 1, 2026
TopicSpinal Muscular Atrophy

Topic: Spinal Muscular Atrophy

Roche patent case: Why SC refused to halt Natco’s generic spinal muscular atrophy drug Risdiplam

Roche had approached Delhi High Court, accusing Natco of violating its Indian patent, before going to the Supreme Court with its petition.

India approves Zolgensma, one of world’s costliest drugs. Why it’s sparked hope, but also concern

Zolgensma is the only drug that promises a cure for Spinal Muscular Atrophy, provided it is administered to affected children before the symptoms appear.

New hope for rare disease patients: Rs 900-cr govt project to get high-value drugs at lower rates in works

India has 8.4 to 19 crore rare disease patients, according to health ministry estimates. But current beneficiaries in most cases are kids or those who need relatively less expensive drugs.

On Camera

The 3 M’s Of Hinduphobia: Mill, Macaulay and Marx

Indians tend to fuss more about the damage done to the Indian psyche by Thomas B Macaulay’s infamous Minute of 1835, but he was preceded in this unholy endeavour by James Mill.

Indian bonds under pressure as RBI forex curbs raise rate hike risk

The RBI’s crackdown on bearish rupee positions may be followed by additional measures, including tighter limits on banks’ positions and further curbs in the offshore currency market, according to Barclays.

More ‘hits’ than Rheinmetall ever—Ukraine drone manufacturer claps back at CEO’s ‘housewives’ remark

Oleksandr Yakovenko, founder of Ukrainian drone maker TAF Industries, further went on to highlight the growing 'irrelevance' of European defence platforms.

Gulf war exposed India’s fragilities. It’s time for navel-gazing, in the national interest

It’s easy to understand why the government can’t speak the hard truth. When this war ends, as all wars do, India’s interests will lie with both the winner and the loser.